Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Avidity Biosciences Inc (RNA) operate in?
Avidity Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Avidity Biosciences Inc (RNA) current stock price?
As of the latest data, Avidity Biosciences Inc stock price is $8.05, with a previous close of $8.20. Avidity Biosciences Inc lost -$0.15 in the last trading session, representing a -1.83% loss.
What is Avidity Biosciences Inc (RNA) current market capitalization?
Avidity Biosciences Inc market cap is approximately 137.70 million.
What is Avidity Biosciences Inc (RNA) Earnings Per Share (EPS)?
The trailing EPS is -$5.44, and the forward EPS is -$8.06.
What is Avidity Biosciences Inc (RNA) EBITDA?
Avidity Biosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -22.27 million.
Does Avidity Biosciences Inc (RNA) pay dividends?
No. Avidity Biosciences Inc does not pay a dividend.
How did Avidity Biosciences Inc (RNA) perform in its most recent earnings report?
In the last report (June 30, 2026), Avidity Biosciences Inc posted an EPS surprise of -84.38% and a revenue surprise of 500.8%.
What is Avidity Biosciences Inc (RNA) beta (volatility) score?
Avidity Biosciences Inc has a beta of 0.930, meaning its volatility is roughly in line with the market.
